Hepatitis B Virus Studies

Moving in Journal of hepatology, Gut, The lancet. Gastroenterology & hepatology, bioRxiv, Nature reviews. Gastroenterology & hepatology, Gastroenterology, JAMA and medRxiv.

Moved, week to 23 Oct 2026: 0
Papers in 60 days: 34

Add Hepatitis B Virus Studies as an interest in JClubFree on iPhone and Android · interests shape Home, Discover and your digest

Rebuilt 23 October 2026 at 3:06 pm AEDT

Moved this week

Everything that moved →

Nothing in this topic has moved yet this week.

Latest in Hepatitis B Virus Studies

Newest first · last 60 days

Time-resolved proteomic analysis of hepatitis B virus infection
bioRxiv · 16 Oct 2026 · Preprint
Read the AI summary in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2026.02.24.707876
Open in JClub
HPV binding antibodies are associated with protection: a meta-analysis
medRxiv · 9 Oct 2026 · Preprint
Read the AI summary in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.1101/2025.11.26.25341002
Open in JClub
Catch me if you can! Is there protection from HCV (re)infection?
Gut · 7 Oct 2026 · Journal Article
Read the AI summary in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/41672760
Open in JClub
Real-world evidence supports earlier treatment in HBeAg-positive but not HBeAg-negative chronic hepatitis B virus infection.
Gut · 7 Oct 2026 · Journal Article
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/41605618
Open in JClub
EASL 2025 indications revisited: phase-specific outcomes with and without nucleos(t)ide analogue therapy in chronic hepatitis B virus infection.
Gut · 7 Oct 2026 · Multicenter Study
Nucleos(t)ide analogues therapy significantly reduces risks of cirrhosis and hepatocellular carcinoma in specific chronic hepatitis B subgroups outside 2025 EASL criteria, especially in HBeAg-positive patients with high replicative or impending phase transition phenotypes.
- Open access
- 6 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/41151792
Open in JClub
Unravelling the heterogeneous HCC risk in indeterminate chronic hepatitis B.
Gut · 7 Oct 2026 · Journal Article
Read the AI summary in JClub
- Open access
- 2 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/40829868
Open in JClub
WHO global hepatitis report 2026: guiding global action for elimination.
The lancet. Gastroenterology & hepatology · 1 Oct 2026 · Journal Article
Read the AI summary in JClub
- 1 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42508445
Open in JClub
From viral clearance to cancer prevention: the next phase of hepatitis elimination.
The lancet. Gastroenterology & hepatology · 1 Oct 2026 · Letter
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42685730
Open in JClub
Launch of the Africa CDC toolkit for hepatitis B: bringing care closer to people in Africa.
The lancet. Gastroenterology & hepatology · 1 Oct 2026 · Journal Article
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42508446
Open in JClub
Sustained Safety and Efficacy of Entecavir Monotherapy for Chronic Hepatitis B After Liver Transplantation: 15-Year Follow-Up.
Gastroenterology · 21 Sept 2026 · Journal Article
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42767282
Open in JClub
High rates of transition to immune active disease in a cohort of strictly defined immune tolerant patients with chronic hepatitis B: results from the RADICAL consortium.
Gut · 18 Sept 2026 · Journal Article
Over 50% of strictly defined immune tolerant chronic hepatitis B patients transition to immune active disease within five years, especially those with high-normal ALT levels.
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42760116
Open in JClub
Occult hepatitis B virus infection.
Nature reviews. Gastroenterology & hepatology · 14 Sept 2026 · Review
Occult hepatitis B virus infection affects up to 40% of individuals with isolated anti-HBc, with prevalence varying from 0.8% in the general population to over 40% in high-risk groups.
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42736448
Open in JClub
Nucleos(t)ide analogue therapy for EASL immune-tolerant phase hepatitis B.
Gut · 7 Sept 2026 · Letter
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/41339058
Open in JClub
Partial cure of chronic hepatitis B: potential implications for HCC surveillance?
Gut · 7 Sept 2026 · Journal Article
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/40730457
Open in JClub
PEG is back: revisiting the role of pegylated interferon alfa and benchmarking its place in HBV cure strategies.
Gut · 7 Sept 2026 · Journal Article
Read the AI summary in JClub
- 2 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/41494801
Open in JClub
HBsAg decline and clearance with peg-IFN therapy added to nucleos(t)ide analogues: an individual participant data meta-analysis of prospective trials (PROSPER).
Gut · 7 Sept 2026 · Meta-Analysis
Adding peg-IFN to nucleos(t)ide analogue therapy achieves HBsAg loss in up to 38% of chronic hepatitis B patients with low initial HBsAg levels.
- Open access
- 5 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/41198171
Open in JClub
Characterisation of plasmablast-derived HBsAg-specific antibody and its structural basis for binding to native HBsAg dimer.
Gut · 7 Sept 2026 · Journal Article
Read the AI summary in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/41663152
Open in JClub
Post-transplant hepatitis D breakthrough driven by integrant-derived HBsAg from an extrahepatic HCC metastasis.
Journal of hepatology · 5 Sept 2026 · Letter
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42700820
Open in JClub
Silent but persistent: Failure of continuous tenofovir based ART to prevent HBV and HDV reactivation under chemotherapy in an HBsAg-negative patient living with HIV.
Journal of hepatology · 2 Sept 2026 · Letter
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42685983
Open in JClub
Genomics-guided therapy in advanced primary liver cancers: A promising yet methodologically challenging landscape.
Journal of hepatology · 1 Sept 2026 · Letter
Read the AI summary in JClub
- 1 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42176808
Open in JClub
siRNA JNJ-73763989 decreases HBsAg and HDV RNA in NA-treated hepatitis D patients but may cause ALT flares.
Journal of hepatology · 1 Sept 2026 · Randomized Controlled Trial
Read the AI summary in JClub
- Open access
- 1 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42142631
Open in JClub
144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and post-treatment results from a phase III randomized trial.
Journal of hepatology · 1 Sept 2026 · Randomized Controlled Trial
Read the AI summary in JClub
- Open access
- 5 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/41966308
Open in JClub
Hepatitis B.
JAMA · 1 Sept 2026 · Journal Article
Acute and chronic hepatitis B affect millions worldwide, with distinct characteristics and outcomes, emphasizing the importance of early diagnosis and management.
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42418208
Open in JClub
When biology pushes back: Lessons from HBsAg-targeting therapies in hepatitis delta.
Journal of hepatology · 1 Sept 2026 · Editorial
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42401242
Open in JClub
Retraction notice to "Safe use of liver grafts from hepatitis B surface antigen positive donors in liver transplantation" [J Hepatol 61 (2014) 809-815].
Journal of hepatology · 1 Sept 2026 · Retraction Notice
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42285819
Open in JClub
Progress and prospects in viral hepatitis elimination.
The lancet. Gastroenterology & hepatology · 1 Sept 2026 · Journal Article
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42556362
Open in JClub
Precision adherence support for hepatitis C treatment.
Nature reviews. Gastroenterology & hepatology · 1 Sept 2026 · Journal Article
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42469389
Open in JClub
Serum HBsAg cannot distinguish cccDNA activity from integrated HBV DNA expression in chronic hepatitis B virus infection.
Journal of hepatology · 29 Aug 2026 · Journal Article
Read the AI summary in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42668120
Open in JClub
Precision-cut liver slices as a model for evaluating therapeutic agents against hepatitis B and delta viruses
bioRxiv · 29 Aug 2026 · Preprint
Read the AI summary in JClub
- Open access
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/10.64898/2025.12.06.692712
Open in JClub
Advancing functional cure for hepatitis B virus infection.
Journal of hepatology · 27 Aug 2026 · Journal Article
Read the AI summary in JClub
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42660744
Open in JClub

Add Hepatitis B Virus Studies as an interest in JClub

Journals this month

All journals →

Topics moving, week to 23 Oct 2026

All topics →

By field

All journals by field →

Moved this week

Latest in Hepatitis B Virus Studies

Browse JClub